However, as described by Yap and colleagues, the targeted cell death caused by PARP inhibitors has the potential to “reset” the tumor microenvironment and polarise the immune response towards a Th1 antitumorigenic profile, resulting in a shift from immune escape to elimination of the tumor [156]. This evidence concerns the gene PARP1 and neoplasm.